$4.70
2.49% yesterday
Nasdaq, Jun 13, 10:06 pm CET
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Agenus Inc. Stock price

$4.70
+1.32 39.05% 1M
+1.65 54.10% 6M
+1.96 71.53% YTD
-11.30 70.63% 1Y
-66.15 93.37% 5Y
-185.08 97.52% 10Y
-693.60 99.33% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.12 2.49%
ISIN
US00847G7051
Symbol
AGEN
Sector
Industry

Key metrics

Market capitalization $128.86m
Enterprise Value $145.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.47
P/S ratio (TTM) P/S ratio 1.29
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -38.35%
Revenue (TTM) Revenue $99.52m
EBIT (operating result TTM) EBIT $-100.90m
Free Cash Flow (TTM) Free Cash Flow $-146.29m
Cash position $18.49m
EPS (TTM) EPS $-7.79
P/E forward negative
P/S forward 1.01
EV/Sales forward 1.15
Short interest 14.25%
Show more

Is Agenus Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Agenus Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

2x Buy
40%
3x Hold
60%

Analyst Opinions

5 Analysts have issued a Agenus Inc. forecast:

Buy
40%
Hold
60%

Financial data from Agenus Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
100 100
38% 38%
100%
- Direct Costs 0.52 0.52
43% 43%
1%
99 99
38% 38%
99%
- Selling and Administrative Expenses 71 71
9% 9%
71%
- Research and Development Expense 133 133
40% 40%
134%
-88 -88
29% 29%
-88%
- Depreciation and Amortization 13 13
9% 9%
13%
EBIT (Operating Income) EBIT -101 -101
27% 27%
-101%
Net Profit -191 -191
20% 20%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about Agenus Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agenus Inc. Stock News

Neutral
Business Wire
4 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www...
Neutral
Business Wire
11 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensil...
Neutral
Business Wire
15 days ago
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic co...
More Agenus Inc. News

Company Profile

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Head office United States
CEO Garo Armen
Employees 316
Founded 1994
Website agenusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today